The P2Y12 receptor (P2Y12R), one of eight members of the P2YR family expressed in humans, is one of the most prominent clinical drug targets for inhibition of platelet aggregation. Although mutagenesis and modelling studies of the P2Y12R provided useful insights into ligand binding1,2,3,4, the agonist and antagonist recognition and function at the P2Y12R remain poorly understood at the molecular level. Here we report the structures of the human P2Y12R in complex with the full agonist 2-methylthio-adenosine-5′-diphosphate (2MeSADP, a close analogue of endogenous agonist ADP) at 2.5 Å resolution, and the corresponding ATP derivative 2-methylthio-adenosine-5′-triphosphate (2MeSATP) at 3.1 Å resolution. These structures, together with the structure of the P2Y12R with antagonist ethyl 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283)5, reveal striking conformational changes between nucleotide and non-nucleotide ligand complexes in the extracellular regions. Further analysis of these changes provides insight into a distinct ligand binding landscape in the δ-group of class A G-protein-coupled receptors (GPCRs). Agonist and non-nucleotide antagonist adopt different orientations in the P2Y12R, with only partially overlapped binding pockets. The agonist-bound P2Y12R structure answers long-standing questions surrounding P2Y12R–agonist recognition, and reveals interactions with several residues that had not been reported to be involved in agonist binding. As a first example, to our knowledge, of a GPCR in which agonist access to the binding pocket requires large-scale rearrangements in the highly malleable extracellular region, the structural and docking studies will therefore provide invaluable insight into the pharmacology and mechanisms of action of agonists and different classes of antagonists for the P2Y12R and potentially for other closely related P2YRs.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Chang, H. et al. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J. Thromb. Haemost. 10, 2573–2580 (2012)
Chang, H. et al. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb. Res. 125, 159–165 (2010)
Schmidt, P. et al. Identification of determinants required for agonistic and inverse agonistic ligand properties at the ADP receptor P2Y12 . Mol. Pharmacol. 83, 256–266 (2013)
Srinivasan, S. et al. The P2Y12 antagonists, 2-methylthioadenosine 5′-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J. Biol. Chem. 284, 16108–16117 (2009)
Zhang, K. et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature http://dx.doi.org/10 1038/nature13083 (this issue)
Zhou, X. E., Melcher, K. & Xu, H. E. Structure and activation of rhodopsin. Acta Pharmacol. Sin. 33, 291–299 (2012)
Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289, 739–745 (2000)
Scheerer, P. et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497–502 (2008)
Warne, T. et al. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454, 486–491 (2008)
Warne, T. et al. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature 469, 241–244 (2011)
Cherezov, V. et al. High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318, 1258–1265 (2007)
Rasmussen, S. G. et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549–555 (2011)
Jaakola, V. P. et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211–1217 (2008)
Xu, F. et al. Structure of an agonist-bound human A2A adenosine receptor. Science 332, 322–327 (2011)
Haga, K. et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547–551 (2012)
Kruse, A. C. et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101–106 (2013)
Fredriksson, R., Lagerstrom, M. C., Lundin, L. G. & Schioth, H. B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256–1272 (2003)
Ballesteros, J. A. & Weinstein, H. in Methods in Neurosciences Vol. 25 (ed. C. Sealfon Stuart ) 366–428 (Academic Press, 1995)
Zhang, C. et al. High-resolution crystal structure of human protease-activated receptor 1. Nature 492, 387–392 (2012)
Rosenbaum, D. M. et al. Structure and function of an irreversible agonist–β2 adrenoceptor complex. Nature 469, 236–240 (2011)
Hoffmann, K., Sixel, U., Di Pasquale, F. & von Kugelgen, I. Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y12-receptor. Biochem. Pharmacol. 76, 1201–1213 (2008)
Cattaneo, M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117, 2102–2112 (2011)
Ignatovica, V., Megnis, K., Lapins, M., Schioth, H. B. & Klovins, J. Identification and analysis of functionally important amino acids in human purinergic 12 receptor using a Saccharomyces cerevisiae expression system. FEBS J. 279, 180–191 (2012)
Daly, M. E. et al. Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 113, 4110–4113 (2009)
Kauffenstein, G., Hechler, B., Cazenave, J. P. & Gachet, C. Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J. Thromb. Haemost. 2, 1980–1988 (2004)
Fujioka, M. & Omori, N. Subtleties in GPCR drug discovery: a medicinal chemistry perspective. Drug Discov. Today 17, 1133–1138 (2012)
Ding, Z., Kim, S. & Kunapuli, S. P. Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor. Mol. Pharmacol. 69, 338–345 (2006)
Zhao, Q. & Wu, B. L. Ice breaking in GPCR structural biology. Acta Pharmacol. Sin. 33, 324–334 (2012)
Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706–731 (2009)
Cherezov, V. et al. Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 μm size X-ray synchrotron beam. J. R. Soc. Interface 6 (Suppl. 5). S587–S597 (2009)
Kabsch, W. XDS. Acta Crystallogr. D 66, 125–132 (2010)
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658–674 (2007)
Vagin, A. A. et al. REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. Acta Crystallogr. D 60, 2184–2195 (2004)
Smart, O. S. et al. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr. D 68, 368–380 (2012)
Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221–234 (2013)
This work was supported by the National Basic Research Program of China grants 2012CB910400, 2012CB518000 and 2014CB910400 (B.W., Q.Z.), the National Institutes of Health grants R01 AI100604 (B.W., Q.Z.) and U54 GM094618 (V.C., V.K., R.C.S.; Target GPCR-87), the National Science Foundation of China grants 31370729 and National Science and Technology Major Project 2013ZX09507001 and 2012ZX09301001 (B.W., Q.Z.), National Institutes of Health NIDDK Intramural Research Program (K.A.J.) and the National Natural Science Foundation of China 91313000 (H.J.). The authors thank S. Nylander, E. Kiselev and S. Moss for scientific feedback on the manuscript, A. Walker for assistance with manuscript preparation and K. Kadyshevskaya for help with figure preparation. The synchrotron radiation experiments were performed at the BL41XU of SPring-8 with the approval of the Japan Synchrotron Radiation Research Institute (JASRI) (proposal no. 2013B1049). We thank the beamline staff members of the BL41XU for help with X-ray data collection.
The authors declare no competing financial interests.
Extended data figures and tables
Extended Data Figure 1 Crystals and electron density of nucleotides for P2Y12R–2MeSADP and P2Y12R–2MeSATP complexes.
a, Crystals of the P2Y12R–2MeSADP complex. The size of the crystals is roughly 80 × 50 × 5 μm. b, Crystals of the P2Y12R–2MeSATP complex. The size of the crystals is roughly 30 × 30 × 5μm. c, The 2mFo–DFc map for the 2MeSADP contoured at 1σ. d, The 2mFo–DFc map for the P2Y12R–2MeSATP contoured at 1σ. The relatively high B-factor of the γ-phosphate group (98 Å2) compared with β-phosphate and surrounding protein atoms (∼75 Å2), and the propensity of 2MeSATP to hydrolyse to 2MeSADP suggest partial occupancy for the γ-phosphate group. However, given the differences in crystal forms and packing, as well as the clear density of the γ-phosphate group, the P2Y12R–2MeSATP complex structure should provide relevant information about 2MeSATP binding.
Extended Data Figure 2 Crystal packing of P2Y12R–2MeSADP, P2Y12R–2MeSATP and P2Y12R–AZD1283 complexes.
a, Overall structure of the P2Y12R–2MeSADP complex, P2Y12R and BRIL are shown in cyan and blue, respectively. b, c, Crystal packing of P2Y12R–2MeSADP complex shown in two different views. d, Overall structure of the P2Y12R–2MeSATP complex, P2Y12R is shown in pink. e, f, Crystal packing of P2Y12R–2MeSATP complex in two different views. g, Overall structure of the P2Y12R–AZD1283 complex, P2Y12R is shown in orange. h, i, Crystal packing of P2Y12R–AZD1283 complex shown in two different views.
Extended Data Figure 3 Comparison of antagonist- (orange) and agonist- (green/cyan) bound P2Y12R structures with the PAR1 structure (yellow).
a, Side view of the three structures. The receptor structures are shown as cylindrical helices and AZD1283 and 2MeSADP are shown as sticks with green carbons and wheat carbons, respectively. b, Comparison view from the extracellular side. c, Comparison view from the intracellular side.
a, Comparison of P2Y12R–AZD1283 (orange) and P2Y12R–2MeSADP (green/cyan). b, Corresponding positions of residues around C973.25 in P2Y12R–AZD1283 (orange) and P2Y12R–2MeSADP (green/cyan).
Extended Data Figure 5 Comparison of pocket 1 (a–c) and pocket 2 (d–f) of P2Y12R structures with different ligands.
a, d, The P2Y12R–2MeSADP structure. b, e, The P2Y12R–2MeSATP structure. c, f, The P2Y12R–AZD1283 structure. The 2MeSADP, 2MeSATP and AZD1283 ligands are shown in sticks with wheat, grey and green carbons, respectively.
Data (mean ± s.e.m.) were determined in triplicate. a, Parallel right shifts induced by antagonist AZD1283 (AZD) of the activation curves by agonist 2MeSADP in inhibition of cAMP production in P2Y12R expressing CHO cells. b, Parallel right shifts induced by antagonist ticagrelor (Tica) of the activation curves by agonist 2MeSADP in inhibition of cAMP production in P2Y12R expressing CHO cells. The pKb values of AZD and Tica are 8.17 ± 0.45 and 7.70 ± 0.18, respectively. c, Partial agonist effects of AR-C66096 (ARC) in inhibition of cAMP production in P2Y12R expressing CHO cells. The half-maximum effective concentration (EC50) value of AR-C66096 was determined to be 34.9 ± 2.9 nM, and its Emax 41.9 ± 3.6% compared with 2MeSADP as 100%. A final concentration of 10 μM forskolin was used in the experiment. DMSO was used as a solvent for the stock solution of forskolin, AZD1283 and ticagrelor. The stock solution of AR-C66096 was made with water.
a, The crystal structure of P2Y12R–2MeSADP complex. b, Docking of 2MeSADP to the P2Y12R structure. c, Docking of ADP to the P2Y12R structure. d, The crystal structure of P2Y12R–2MeSATP complex. e, Docking of 2MeSATP to the P2Y12R structure. f, Docking of ATP to the P2Y12R structure. g, Docking of AR-C66096 to the P2Y12R structure. h, Docking of AR-C67085 to the P2Y12R structure. i, Docking of AR-C69931MX (cangrelor) to the P2Y12R structure. 2MeSADP and 2MeSATP poses from corresponding crystal structures are shown in stick with orange and grey carbons, respectively. Docking was performed to the conformation of P2Y12R found in the 2MeSADP-bound structure, and the docked ligands are shown in sticks with purple carbons. AR-C66096 and AR-C67085 show the same interactions observed in the 2MeSADP complex. In addition, the C2-propylthio substituent of AR-C66096 and AR-C67085 is located in a hydrophobic pocket in proximity to helix IV surrounded by F1063.34, Y1093.37, M1524.53 and L1554.56. The γ-phosphonate group is directed towards helix III and interacts with K802.60 and R933.21. The C2 substituent and the γ-phosphonate group of AR-C69931MX show similar orientation as observed in the docking pose of AR-C66096 and AR-C67085. The N6 substituent is directed towards helix VI in proximity to Y1093.37, Q1955.44, F2526.51, H2536.52 and R256 6.55.
The chemical structures of parts of ligands that are discussed and used in the docking studies are shown. Ticagrelor and AR-C78511 could not be docked in a conformation similar to 2MeSADP because the presence of their bulky N6substituents would cause a steric clash with helices V and VI. AR-C78511 was previously shown to lack partial agonist properties.
About this article
Cite this article
Zhang, J., Zhang, K., Gao, ZG. et al. Agonist-bound structure of the human P2Y12 receptor. Nature 509, 119–122 (2014). https://doi.org/10.1038/nature13288
This article is cited by
GSDMD knockdown attenuates phagocytic activity of microglia and exacerbates seizure susceptibility in TLE mice
Journal of Neuroinflammation (2023)
Molecular Biomedicine (2022)
Nature Protocols (2022)
Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target
Inflammation Research (2021)
That was then, this is now: the development of our knowledge and understanding of P2 receptor subtypes
Purinergic Signalling (2021)